Venlafaxine Hydrochloride Patent Expiration
Venlafaxine Hydrochloride is Used for treating depression, generalized anxiety disorder, panic disorder, and social anxiety disorder. It was first introduced by Wyeth Pharmaceuticals Inc
Venlafaxine Hydrochloride Patents
Given below is the list of patents protecting Venlafaxine Hydrochloride, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Effexor Xr |
US6274171 (Pediatric) | Extended release formulation of venlafaxine hydrochloride |
Sep 20, 2017
(Expired) | Upjohn |
| Effexor Xr |
US6403120 (Pediatric) | Extended release formulation of venlafaxine hydrochloride |
Sep 20, 2017
(Expired) | Upjohn |
| Effexor Xr |
US6419958 (Pediatric) | Extended release formulation of venlafaxine hydrochloride |
Sep 20, 2017
(Expired) | Upjohn |
| Effexor Xr | US6274171 | Extended release formulation of venlafaxine hydrochloride |
Mar 20, 2017
(Expired) | Upjohn |
| Effexor Xr | US6403120 | Extended release formulation of venlafaxine hydrochloride |
Mar 20, 2017
(Expired) | Upjohn |
| Effexor Xr | US6419958 | Extended release formulation of venlafaxine hydrochloride |
Mar 20, 2017
(Expired) | Upjohn |
| Venlafaxine Hydrochloride | US6403120 | Extended release formulation of venlafaxine hydrochloride |
Mar 20, 2017
(Expired) | Osmotica Pharm Us |
| Venlafaxine Hydrochloride | US6419958 | Extended release formulation of venlafaxine hydrochloride |
Mar 20, 2017
(Expired) | Osmotica Pharm Us |
| Effexor Xr |
US5916923 (Pediatric) | Venlafaxine for the treatment of generalized anxiety disorder |
Dec 28, 2013
(Expired) | Upjohn |
| Effexor Xr |
US6444708 (Pediatric) | Treatment using venlafaxine |
Dec 28, 2013
(Expired) | Upjohn |
| Effexor Xr | US5916923 | Venlafaxine for the treatment of generalized anxiety disorder |
Jun 28, 2013
(Expired) | Upjohn |
| Effexor Xr | US6310101 | Treatments using venlafaxine |
Jun 28, 2013
(Expired) | Upjohn |
| Effexor Xr | US6444708 | Treatment using venlafaxine |
Jun 28, 2013
(Expired) | Upjohn |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or
decrease the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that
drug. Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in
the patent process of
the drug which can give an idea of how early a drug's generic could be available. The next
section provides a list
of recent legal activities on Venlafaxine Hydrochloride's patents.
Latest Legal Activities on Venlafaxine Hydrochloride's Patents
Given below is the list recent legal activities going on the following patents of Venlafaxine Hydrochloride.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent Issue Date Used in PTA Calculation | 16 Jul, 2002 | US6419958 |
| Recordation of Patent Grant Mailed | 16 Jul, 2002 | US6419958 |
| Issue Notification Mailed | 27 Jun, 2002 | US6419958 |
| Receipt into Pubs | 18 Jun, 2002 | US6419958 |
| Receipt into Pubs | 13 Jun, 2002 | US6419958 |
| Recordation of Patent Grant Mailed | 11 Jun, 2002 | US6403120 |
| Patent Issue Date Used in PTA Calculation | 11 Jun, 2002 | US6403120 |
| Issue Notification Mailed | 24 May, 2002 | US6403120 |
| Application Is Considered Ready for Issue | 24 May, 2002 | US6419958 |
| Issue Fee Payment Received | 20 May, 2002 | US6419958 |
Venlafaxine Hydrochloride's Family Patents
